FOLH1 and posterior cortical atrophy: This outcome, while demonstrating clear biological activity, is highly significant: it strongly suggests that a single cycle of 177Lu-PSMA-617 monotherapy is insufficient to completely eradicate macroscopic, high-risk localized PCa.